Lycia Therapeutics, Inc. (LYCA)

Lycia Therapeutics will go public soon, but the exact IPO date is still unknown.

Stock Price: Pending

IPO price not available yet

Lycia Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Revenue	4.44	6.74	14.94
Revenue Growth	-	-54.87%	-
Gross Profit	4.44	6.74	14.94
Selling, General & Admin	-	6.11	6.4
Research & Development	-	40.51	41.07
Other Operating Expenses	0	1.53	0
Operating Expenses	-	48.15	47.47
Operating Income	-33.93	-41.41	-32.53
Interest Expense (Income)	-3.7	-4.8	-6.15
Other Expense (Income)	0.05	0.1	0.12
Pretax Income	-30.28	-36.71	-26.5
Income Tax	-0.25	-0.25	0.01
Net Income	-30.03	-36.46	-26.5

Additional Metrics

Year Ending	TTM	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Free Cash Flow	-33.79	-51.56	-30.77
Free Cash Flow Growth	-	-	-
Gross Margin	100.00%	100.00%	100.00%
Operating Margin	-765.05%	-614.24%	-217.82%
Profit Margin	-677.16%	-540.87%	-177.44%
Free Cash Flow Margin	-761.83%	-764.81%	-206.03%
EBITDA	-33.01	-40.32	-31.47
EBITDA Margin	-744.22%	-598.10%	-210.73%
Depreciation & Amortization	0.97	1.19	1.18
EBIT	-33.98	-41.51	-32.65
EBIT Margin	-766.18%	-615.75%	-218.60%